Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

88.00 +0.51 (+0.58%)
Official Closing Price Updated: 4:10 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,216,205
Open 87.51
Bid (Size) 87.93 (1)
Ask (Size) 88.00 (3)
Prev. Close 87.49
Today's Range 87.03 - 88.30
52wk Range 73.31 - 105.11
Shares Outstanding 2,531,374,696
Dividend Yield 3.68%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Dividend-Paying Drug Stocks to Buy at a Discount
Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying? 
Via The Motley Fool
Topics Intellectual Property
How Is The Market Feeling About Merck & Co Inc?
 
Via Benzinga

Performance

YTD
-11.3%
-11.3%
1 Month
+12.0%
+12.0%
3 Month
+4.7%
+4.7%
6 Month
+5.8%
+5.8%
1 Year
-15.6%
-15.6%

More News

Read More
3 Healthcare Stocks to Buy Hand Over Fist in October
Via The Motley Fool
Topics Intellectual Property
U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study
From Merck & Co., Inc.
Via Business Wire
Merck & Co Unusual Options Activity
Via Benzinga
3 Healthcare Stocks That Are Screaming Deals Right Now
Via The Motley Fool
Topics Intellectual Property
Flash PMI: The Early Warning System Guiding the Federal Reserve's Hand
Via MarketMinute
Topics Bonds Economy Supply Chain
ONEOK’s 6% Dividend Draws Smart Money Despite a Nearly 30% Drop
Via The Motley Fool
Topics Energy Regulatory Compliance
Why Some Investors Are Taking Profits on JPMorgan After Its Big Rally
Via The Motley Fool
Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025
From Merck & Co., Inc.
Via Business Wire
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer
From Merck & Co.
Via Business Wire
AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare
Via TokenRing AI
Topics Animal Testing Artificial Intelligence
Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults
From Merck & Co., Inc.
Via Business Wire
Market Minute: Dow Soars, Apple Hits Record High as 20-Day Government Shutdown Fuels Gold Rally
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
What's Going On With Summit Therapeutics Stock On Monday?
Via Benzinga
2 Beaten-Down Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia
From Merck & Co., Inc.
Via Business Wire
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
From Daiichi Sankyo
Via Business Wire
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients
Via Investor's Business Daily
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
From Merck & Co., Inc.
Via Business Wire
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
From Merck & Co., Inc.
Via Business Wire
Healthcare’s AI Revolution: Generative Intelligence Delivers Real Returns as Agentic Systems Drive Measurable Outcomes
Via TokenRing AI
Topics Artificial Intelligence Economy

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 88.00
When was Merck & Co last traded?
The last trade of Merck & Co was at 10/27/25 04:10 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 222.76B
How many shares of Merck & Co are outstanding?
Merck & Co has 223B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.